Measurements of quality of life in patients with growth hormone deficiency.
Decreased quality of life (QoL) is a common feature of adults with GH deficiency (GHD) and is an important measure of efficacy of treatment. A number of tools have been used to measure QoL in studies of GHD patients, including both generic [e.g. Nottingham Health Profile (NHP); Psychological General Well Being Scale (PGWB)] and disease-specific questionnaires [e.g. Questions on Life Satisfaction Hypopituitarism (QLS-H) and Adult Growth Hormone Deficiency Assessment (AGHDA)]. This paper reviews QoL data in GHD patients as measured by both generic and disease-specific questionnaires. Results using generic tools tend to show worse baseline scores than the general population; however, since they do not contemplate dimensions specifically affected in patients with adult GHD, results after replacement with GH do not always show a significant improvement. The results from disease-specific tools invariably report an improvement of QoL in GHD patients upon GH replacement therapy, if it was abnormal at baseline. QoL data from the HypoCCS study, measured using the QLS-H questionnaire, show that pre-treatment QoL is significantly lower in adults with GHD than in the general population, but on treatment with GH replacement therapy, improvements in QoL are observed and maintained long-term over several years.
Webb
S M
SM
Endocrinology Department, ISCIII; Hospital Sant Pau, Autonomous University of Barcelona, 08025-Barcelona, Spain. swebb@santpau.cat
D005500:Follow-Up Studies; D006130:Growth Disorders / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology*; D019382:Human Growth Hormone / Q000172:deficiency* / Q000627:therapeutic use; D006801:Humans; D007018:Hypopituitarism / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology*; D017063:Outcome Assessment, Health Care; D011788:Quality of Life; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome
D019382:Human Growth Hormone